Yu C, Huang F, Wang L, Liu M, Chow W, Ling X
Cancers (Basel). 2025; 17(5).
PMID: 40075728
PMC: 11899045.
DOI: 10.3390/cancers17050881.
Daunov M, Van Besien K
Cells. 2024; 13(21.
PMID: 39513887
PMC: 11545473.
DOI: 10.3390/cells13211780.
Dong X, Zhang J
Toxicol Rep. 2024; 12:430-435.
PMID: 38618137
PMC: 11015445.
DOI: 10.1016/j.toxrep.2024.04.001.
Robles-Banuelos B, Romo-Perez A, Dominguez-Gomez G, Chavez-Blanco A, Gonzalez-Fierro A, Duenas-Gonzalez A
Clin Transl Oncol. 2023; 26(5):1077-1088.
PMID: 38064014
DOI: 10.1007/s12094-023-03352-w.
Gautam R, Mittal P, Goyal R, Dua K, Mishra D, Sharma S
Curr Med Chem. 2023; 31(28):4479-4494.
PMID: 37828674
DOI: 10.2174/0109298673258987231004092334.
Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma.
Klingberg D, Bae S, Zhou D, Sim H, Cai R, Anazodo A
Asia Pac J Clin Oncol. 2023; 21(1):87-94.
PMID: 37566390
PMC: 11733862.
DOI: 10.1111/ajco.13998.
Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives.
Panthi V, Dua K, Singh S, Gupta G, Hansbro P, Paudel K
Pharmaceutics. 2023; 15(4).
PMID: 37111677
PMC: 10146318.
DOI: 10.3390/pharmaceutics15041192.
Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment.
Wonders K, Schmitz K, Harness J
Integr Cancer Ther. 2023; 22:15347354231168368.
PMID: 37077136
PMC: 10126785.
DOI: 10.1177/15347354231168368.
Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer.
Nyrop K, Monaco J, Vohra S, Deal A, Wood W, Shachar S
Support Care Cancer. 2023; 31(3):196.
PMID: 36859693
DOI: 10.1007/s00520-023-07637-2.
Genetically Engineered Nanoparticles of Asymmetric Triblock Polypeptide with a Platinum(IV) Cargo Outperforms a Platinum(II) Analog and Free Drug in a Murine Cancer Model.
Saha S, Banskota S, Liu J, Zakharov N, Dzuricky M, Li X
Nano Lett. 2022; 22(14):5898-5908.
PMID: 35839459
PMC: 9912577.
DOI: 10.1021/acs.nanolett.2c01850.
Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review.
Mora J
Cancers (Basel). 2022; 14(11).
PMID: 35681553
PMC: 9179268.
DOI: 10.3390/cancers14112572.
Metronomic Therapy in Oral Squamous Cell Carcinoma.
Su N, Chen Y
J Clin Med. 2021; 10(13).
PMID: 34206730
PMC: 8269021.
DOI: 10.3390/jcm10132818.
Case Report: Response to Intra-arterial Cisplatin and Concurrent Radiotherapy Followed by Salvage Surgery in a Patient With Advanced Primary Sinonasal Low-Grade Non-intestinal Adenocarcinoma.
Tachino H, Takakura H, Shojaku H, Fujisaka M, Akaogi K, Kawabe H
Front Surg. 2020; 7:599392.
PMID: 33363200
PMC: 7758204.
DOI: 10.3389/fsurg.2020.599392.
Expected and paradoxical effects of obesity on cancer treatment response.
Gallo M, Adinolfi V, Barucca V, Prinzi N, Renzelli V, Barrea L
Rev Endocr Metab Disord. 2020; 22(4):681-702.
PMID: 33025385
DOI: 10.1007/s11154-020-09597-y.
Superparamagnetic Iron Oxide Nanoparticles Carrying Chemotherapeutics Improve Drug Efficacy in Monolayer and Spheroid Cell Culture by Enabling Active Accumulation.
Nguyen K, Nuss B, Muhlberger M, Unterweger H, Friedrich R, Alexiou C
Nanomaterials (Basel). 2020; 10(8).
PMID: 32796757
PMC: 7466387.
DOI: 10.3390/nano10081577.
Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients.
Aigner K, Gailhofer S, Selak E, Aigner K
J Cancer Res Clin Oncol. 2019; 145(11):2855-2862.
PMID: 31506738
PMC: 6800855.
DOI: 10.1007/s00432-019-03019-6.
The rationale of dose-response curves in selecting cancer drug dosing.
Martin J, Dimmitt S
Br J Clin Pharmacol. 2019; 85(10):2198-2204.
PMID: 31077412
PMC: 6783605.
DOI: 10.1111/bcp.13979.
Delivering Combination Chemotherapies and Targeting Oncogenic Pathways via Polymeric Drug Delivery Systems.
Nair P
Polymers (Basel). 2019; 11(4).
PMID: 30959799
PMC: 6523645.
DOI: 10.3390/polym11040630.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Kude de Almeida F, Dornelles Rosa D
Breast Care (Basel). 2019; 13(6):447-452.
PMID: 30800040
PMC: 6381879.
DOI: 10.1159/000488026.
The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
Dlugosz-Danecka M, Szmit S, Ogorka T, Skotnicki A, Jurczak W
Cancer Med. 2019; 8(3):1103-1109.
PMID: 30740919
PMC: 6434223.
DOI: 10.1002/cam4.2008.
